Promising Prospects for Upstream Bio’s Verekitug: A Potential Blockbuster in Inflammatory Disease Treatment
Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due ...
Positive Buy Rating for Upstream Bio Driven by Verekitug’s Potential in Severe Asthma and Expansion into CRSwNP and COPD Markets
Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...
Life science firm's $76M expansion to boost volume at Wisconsin plants
MilliporeSigma has about 1,700 employees in Wisconsin at facilities in Milwaukee, Port Washington, Sheboygan and in the ...
TipRanks on MSN19h
Upstream Bio initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is ...